44 Wealth Management LLC Increases Stock Holdings in Humana Inc. (NYSE:HUM)

44 Wealth Management LLC raised its stake in shares of Humana Inc. (NYSE:HUM) by 53.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,567 shares of the insurance provider’s stock after acquiring an additional 896 shares during the period. 44 Wealth Management LLC’s holdings in Humana were worth $679,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Humana by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock valued at $244,811,000 after acquiring an additional 65,735 shares during the last quarter. denkapparat Operations GmbH bought a new stake in shares of Humana during the 4th quarter worth $323,000. Allstate Corp purchased a new position in shares of Humana in the 4th quarter worth about $905,000. Deutsche Bank AG grew its position in Humana by 18.2% during the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider’s stock valued at $160,185,000 after buying an additional 97,071 shares during the period. Finally, Janney Montgomery Scott LLC bought a new stake in Humana in the first quarter worth about $1,309,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Down 2.1%

Shares of HUM stock opened at $238.58 on Friday. The stock has a market cap of $28.79 billion, a P/E ratio of 16.87, a P/E/G ratio of 1.84 and a beta of 0.44. Humana Inc. has a 12 month low of $212.45 and a 12 month high of $406.46. The company has a 50 day simple moving average of $240.79 and a two-hundred day simple moving average of $258.69. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analysts’ expectations of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the business posted $7.23 earnings per share. On average, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio (DPR) is presently 25.04%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Robert W. Baird increased their target price on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, April 15th. Wall Street Zen raised Humana from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Guggenheim assumed coverage on Humana in a research report on Wednesday, April 9th. They set a “buy” rating and a $326.00 price target on the stock. Mizuho lifted their price objective on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. Finally, Raymond James Financial raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Sixteen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $280.76.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.